Pochopien, Donald J.Morley, Kimberly L.Blackburn, Robert P.
인용정보
피인용 횟수 :
9인용 특허 :
43
초록▼
The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form,
The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form, the cells expressing the Fas ligand are useful in vitro for identifying Fas expressing cells and in vitro or in vivo for reducing populations of Fas expressing cells. Thus, in other embodiments, the present invention is also directed to a method for treating a patient, for example a mammal, for autoimmune disease or transplant rejection by administering a Fas ligand therapeutic agent. The therapeutic agent is a polypeptide, a polynucleotide encoding the polypeptide or a small molecule. The polypeptides include full-length Fas ligand polypeptide, or a biologically active variant, derivative, portion, fusion or peptide thereof.
대표청구항▼
The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form,
The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form, the cells expressing the Fas ligand are useful in vitro for identifying Fas expressing cells and in vitro or in vivo for reducing populations of Fas expressing cells. Thus, in other embodiments, the present invention is also directed to a method for treating a patient, for example a mammal, for autoimmune disease or transplant rejection by administering a Fas ligand therapeutic agent. The therapeutic agent is a polypeptide, a polynucleotide encoding the polypeptide or a small molecule. The polypeptides include full-length Fas ligand polypeptide, or a biologically active variant, derivative, portion, fusion or peptide thereof. Responses Correlate with Recovery from Cytomegalovirus Infection in Bone-Marrow-Transplant Recipients", The New England Journal of Medicine, Cytomegalovirus Infection 307(1):7-13 (1982). Ralston et al., "Characterization of Hepatitis C Virus Envelope Glycoprotein Complexes Expressed by Recombinant Vaccinia Viruses", Journal of Virology 67(11):6753-6761 (1993). Rasmussen, "Immune Response to Human Cytomegalovirus Infection", Current Topics in Microbiology and Immunology 154:222-254 (1990). Retiere et al., "Generation of Cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells with Stable Expression of pp65 or IE1 Proteins: a Tool to Study the Fine Specificity of the Antiviral Response," J. Of Virology 74(9):3948-3952, May 2000. Reusser et al., "Cytotoxic T-Lymphocyte Response to Cytomegalovirus After Human Allogeneic Bone Marrow Transplantation: Pattern of Recovery and Correlation With Cytomegalovirus Infection and Disease", Blood 78(5):1373-1380(1991). Riddell et al., "Therapeutic Reconstitution of Human Viral Immunity by Adoptive Transfer of Cytotoxic T Lymphocyte Clones", CurrentTopics in Microbiology and Immunology 189:9-34 (1994). Riddell et al., "Restoration of Viral Immunodeficient Humans by the Adoptive Transfer of T Cell Clones", Science 257:238-241 (1992). Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis", Science 265:391-394 (1994). Tobery et al
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (43)
Muzyczka Nicholas (Stony Brook NY) Hermonat Paul L. (Bethesda MD) Berns Kenneth I. (Mamaroneck NY) Samulski Richard J. (Princeton NJ), AAV transduction vectors.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Suni Jukka (Helsinki FIX) Vaheri Antti (Helsinki FIX), Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus.
Huang Henry V. (University City MO) Levis Robin (Takoma Park MD) Rice Charles M. (University City MO) Schlesinger Sondra (University City MO) Shen Ping (University City MO) Xiong Cheng (St. Louis MO), Infectious Sindbis virus vectors.
Stephen Robert L. (2501 Kensington Ave. Salt Lake City UT 84108) Lugnani Franco (Viale Miramare 23 34135 Trieste ITX) Rossi Cino (Via Settala 32 00123 Roma ITX) Eruzzi Silvio (Via A. Mori ; 23 46100 , Intracorporeal iontophoretic method.
Vande Woude George F. (Berryville VA) McClements William L. (Silver Spring MD) Oskarsson Marianne K. (Bethesda MD) Blair Donald G. (Kensington MD), LTR-Vectors.
Goeddel David V. (Hillsborough CA) Rice Glenn C. (Palo Alto CA) Leung David W. H. (Foster City CA), Method for making variant secreted proteins with altered properties.
Dull Thomas J. (San Francisco CA) Riedel Heimo (San Francisco CA) Ullrich Axel (San Francisco CA), Novel receptors for efficient determination of ligands and their antagonists or agonists.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Lebkowski Jane S. (Portola Valley CA) McNally Maureen A. (Palo Alto CA) Okarma Thomas B. (Palo Alto CA), Production of recombinant adeno-associated virus vectors.
Lebkowski Jane S. (Portola Valley CA) McNally Maureen A. (Palo Alto CA) Okarma Thomas B. (Palo Alto CA), Production of recombinant adeno-associated virus vectors.
Schlesinger Sondra (St. Louis MO) Huang Henry V. (St. Louis MO) Levis Robin (Takoma Park MD) Weiss Barbara (Clayton MO) Tsiang Manuel (St. Louis MO), Sindbis virus vectors.
Robinson, William H.; Hirschberg, David L.; Steinman, Lawrence; Ruiz, Pedro Jose; Utz, Paul J.; Garren, Hideki, Therapeutic and diagnostic uses of antibody specificity profiles.
Braun, Serge, Use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.